Aaron Kowalski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aaron Kowalski has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Richard M. Bergenstal
International Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA
5 shared publications Kelly L. Close
Close Concerns and The diaTribe Foundation, San Francisco, CA
4 shared publications- Kirsten Nørgaard
Diabetes Technology Research, Steno Diabetes Center Copenhagen, Herlev, Denmark
4 shared publications Lutz Heinemann
Science Consulting in Diabetes, Neuss, Germany
4 shared publications- Roy W. Beck
Jaeb Center for Health Research, Tampa, Florida, USA
4 shared publications - Simon Heller
Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK
4 shared publications
Latest Publications
- Open Access
- 11 April 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (6) , 1063-1076
The Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes
Despite significant progress, type 1 diabetes (T1D) still results in premature death, significant complications, and a substantial daily burden for those affected. T1D remains a lifelong condition that demands constant vigilance and resilience and has a significant social and economic impact. Individuals with T1D must walk a tightrope to minimize disease-related complications that result from insufficient insulin while also avoiding adverse effects from too much insulin. Achieving this balance is challenging, as diet, activity, medications, physiology, the environment, stress, and many other aspects of daily living all affect glucose levels, often differently from day to day. Persistent challenges of T1D go beyond maintaining glycemic control and include managing long-term complications and preventing potentially life-threating adverse reactions from insulin therapy, and the emotional and cognitive burdens that often lead to diabetes distress and burnout. The T1D community—researchers, sponsors, clinicians, those living with T1D, and advocates—must look beyond managing symptoms of T1D and aim for better treatments and to bring cures. Emerging therapies need clear and efficient regulatory pathways, and new solutions are needed to address ongoing regulatory challenges. The perspectives of people with T1D must be front and center in research and regulatory decision-making. Through the collective efforts of the T1D community, the urgent needs of those with T1D can be met, and T1D can be made a thing of the past.
- 11 April 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (6) , 1063-1076
Open AccessThe Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes
Despite significant progress, type 1 diabetes (T1D) still results in premature death, significant complications, and a substantial daily burden for those affected. T1D remains a lifelong condition that demands constant vigilance and resilience and has a significant social and economic impact. Individuals with T1D must walk a tightrope to minimize disease-related complications that result from insufficient insulin while also avoiding adverse effects from too much insulin. Achieving this balance is challenging, as diet, activity, medications, physiology, the environment, stress, and many other aspects of daily living all affect glucose levels, often differently from day to day. Persistent challenges of T1D go beyond maintaining glycemic control and include managing long-term complications and preventing potentially life-threating adverse reactions from insulin therapy, and the emotional and cognitive burdens that often lead to diabetes distress and burnout. The T1D community—researchers, sponsors, clinicians, those living with T1D, and advocates—must look beyond managing symptoms of T1D and aim for better treatments and to bring cures. Emerging therapies need clear and efficient regulatory pathways, and new solutions are needed to address ongoing regulatory challenges. The perspectives of people with T1D must be front and center in research and regulatory decision-making. Through the collective efforts of the T1D community, the urgent needs of those with T1D can be met, and T1D can be made a thing of the past.
- Open Access
- 20 May 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (6) , 918-920
Automated Insulin Delivery: A Milestone on the Road to Insulin Independence in Type 1 Diabetes
Despite recent advances in our understanding and treatment of type 1 diabetes, the burden remains vast and is expected to increase rapidly, especially in r Despite recent advances in our understanding and treatment of type 1 diabetes, the burden remains vast and is expected to increase rapidly, especially in r
- 20 May 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (6) , 918-920
Open AccessAutomated Insulin Delivery: A Milestone on the Road to Insulin Independence in Type 1 Diabetes
Despite recent advances in our understanding and treatment of type 1 diabetes, the burden remains vast and is expected to increase rapidly, especially in r Despite recent advances in our understanding and treatment of type 1 diabetes, the burden remains vast and is expected to increase rapidly, especially in r
- Open Access
- 4 February 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (4) , 935-938
Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]
- 4 February 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (4) , 935-938
Open AccessGlucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]
- Open Access
- 13 October 2020
- Published by Springer Nature in Diabetologia
- Vol. 63 (12) , 2501-2520
Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)
Physical exercise is an important component in the management of type 1 diabetes across the lifespan. Yet, acute exercise increases the risk of dysglycaemia, and the direction of glycaemic excursions depends, to some extent, on the intensity and duration of the type of exercise. Understandably, fear of hypoglycaemia is one of the strongest barriers to incorporating exercise into daily life. Risk of hypoglycaemia during and after exercise can be lowered when insulin-dose adjustments are made and/or additional carbohydrates are consumed. Glycaemic management during exercise has been made easier with continuous glucose monitoring (CGM) and intermittently scanned continuous glucose monitoring (isCGM) systems; however, because of the complexity of CGM and isCGM systems, both individuals with type 1 diabetes and their healthcare professionals may struggle with the interpretation of given information to maximise the technological potential for effective use around exercise (i.e. before, during and after). This position statement highlights the recent advancements in CGM and isCGM technology, with a focus on the evidence base for their efficacy to sense glucose around exercise and adaptations in the use of these emerging tools, and updates the guidance for exercise in adults, children and adolescents with type 1 diabetes. Graphical abstract
- 13 October 2020
- Published by Springer Nature in Diabetologia
- Vol. 63 (12) , 2501-2520
Open AccessGlucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)
Physical exercise is an important component in the management of type 1 diabetes across the lifespan. Yet, acute exercise increases the risk of dysglycaemia, and the direction of glycaemic excursions depends, to some extent, on the intensity and duration of the type of exercise. Understandably, fear of hypoglycaemia is one of the strongest barriers to incorporating exercise into daily life. Risk of hypoglycaemia during and after exercise can be lowered when insulin-dose adjustments are made and/or additional carbohydrates are consumed. Glycaemic management during exercise has been made easier with continuous glucose monitoring (CGM) and intermittently scanned continuous glucose monitoring (isCGM) systems; however, because of the complexity of CGM and isCGM systems, both individuals with type 1 diabetes and their healthcare professionals may struggle with the interpretation of given information to maximise the technological potential for effective use around exercise (i.e. before, during and after). This position statement highlights the recent advancements in CGM and isCGM technology, with a focus on the evidence base for their efficacy to sense glucose around exercise and adaptations in the use of these emerging tools, and updates the guidance for exercise in adults, children and adolescents with type 1 diabetes. Graphical abstract
- Top Cited Papers
- 8 June 2019
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (8) , 1593-1603
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
- 8 June 2019
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (8) , 1593-1603
Top Cited PapersClinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
- Open Access
- 17 December 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (2) , e29-e30
Response to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018;41:2275–2280
- 17 December 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (2) , e29-e30
Open AccessResponse to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018;41:2275–2280
- Top Cited Papers
- 17 September 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (11) , 2275-2280
Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring
While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help facilitate safe and effective diabetes management, it is important to understand how CGM metrics, such as mean glucose, and A1C correlate. Estimated A1C (eA1C) is a measure converting the mean glucose from CGM or self-monitored blood glucose readings, using a formula derived from glucose readings from a population of individuals, into an estimate of a simultaneously measured laboratory A1C. Many patients and clinicians find the eA1C to be a helpful educational tool, but others are often confused or even frustrated if the eA1C and laboratory-measured A1C do not agree. In the U.S., the Food and Drug Administration determined that the nomenclature of eA1C needed to change. This led the authors to work toward a multipart solution to facilitate the retention of such a metric, which includes renaming the eA1C the glucose management indicator (GMI) and generating a new formula for converting CGM-derived mean glucose to GMI based on recent clinical trials using the most accurate CGM systems available. The final aspect of ensuring a smooth transition from the old eA1C to the new GMI is providing new CGM analyses and explanations to further understand how to interpret GMI and use it most effectively in clinical practice. This Perspective will address why a new name for eA1C was needed, why GMI was selected as the new name, how GMI is calculated, and how to understand and explain GMI if one chooses to use GMI as a tool in diabetes education or management.
- 17 September 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (11) , 2275-2280
Top Cited PapersGlucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring
While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help facilitate safe and effective diabetes management, it is important to understand how CGM metrics, such as mean glucose, and A1C correlate. Estimated A1C (eA1C) is a measure converting the mean glucose from CGM or self-monitored blood glucose readings, using a formula derived from glucose readings from a population of individuals, into an estimate of a simultaneously measured laboratory A1C. Many patients and clinicians find the eA1C to be a helpful educational tool, but others are often confused or even frustrated if the eA1C and laboratory-measured A1C do not agree. In the U.S., the Food and Drug Administration determined that the nomenclature of eA1C needed to change. This led the authors to work toward a multipart solution to facilitate the retention of such a metric, which includes renaming the eA1C the glucose management indicator (GMI) and generating a new formula for converting CGM-derived mean glucose to GMI based on recent clinical trials using the most accurate CGM systems available. The final aspect of ensuring a smooth transition from the old eA1C to the new GMI is providing new CGM analyses and explanations to further understand how to interpret GMI and use it most effectively in clinical practice. This Perspective will address why a new name for eA1C was needed, why GMI was selected as the new name, how GMI is calculated, and how to understand and explain GMI if one chooses to use GMI as a tool in diabetes education or management.
- Top Cited Papers
- 10 November 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (12) , 1631-1640
International Consensus on Use of Continuous Glucose Monitoring
Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
- 10 November 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (12) , 1631-1640
Top Cited PapersInternational Consensus on Use of Continuous Glucose Monitoring
Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
- Open Access
- 19 March 2001
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (3) , 578-584
Osteopontin: An intrinsic inhibitor of inflammation in cartilage
- 19 March 2001
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (3) , 578-584
Open AccessOsteopontin: An intrinsic inhibitor of inflammation in cartilage